A Systematic Review of Financial Toxicity Among Cancer Survivors: We Can’t Pay the Co-Pay

Patient

Volumn 10, Issue 3, 2017, Pages 295-309

  Gordon, Louisa G ^a   Merollini, Katharina M D ^b   Lowe, Anthony ^c,d   Chan, Raymond J ^e,f  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF THE SUNSHINE COAST   (Australia)

^c PROSTATE CANCER FOUNDATION OF AUSTRALIA   (Australia)

^d GRIFFITH UNIVERSITY   (Australia)

^e QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^f ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PATIENT; CANCER SURVIVOR; FINANCIAL MANAGEMENT; FINANCIAL TOXICITY; HEALTH CARE COST; HUMAN; LOWEST INCOME GROUP; MALIGNANT NEOPLASM; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW; COST; CROSS-SECTIONAL STUDY; ECONOMICS; STATISTICS AND NUMERICAL DATA;

CANCER SURVIVORS; COST SHARING; CROSS-SECTIONAL STUDIES; FINANCING, PERSONAL; HEALTH EXPENDITURES; HUMANS;

EID: 84992727865     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.1007/s40271-016-0204-x     Document Type: Review

References (42)

1. de Souza JA, Wong Y-N. Financial distress in cancer patients. J Med Person. 2013;11(2):73–7. doi:10.1007/s12682-013-0152-3.
2. Yabroff KR, Lawrence WF, Clauser S, et al. Burden of illness in cancer survivors: findings from a population-based national sample. J Natl Cancer Inst. 2004;96(17):1322–30.
3. Laba TL, Essue BM, Jan S. Financing options to sustain Medicare: are we committed to universalism? Med J Aust. 2015;203(6):244.e1–245.e1.
4. Tucker-Seeley RD, Yabroff KR. Minimizing the “financial toxicity” associated with cancer care: advancing the research agenda. J Natl Cancer Inst. 2016;108(5):djv410. doi:10.1093/jnci/djv410.
5. Zafar SY. Financial toxicity of cancer care: it’s time to intervene. J Natl Cancer Inst. 2016;108(5):djv370. doi:10.1093/jnci/djv370.
6. Jan S, Kimman M, Peters SA, Woodward M. Financial catastrophe, treatment discontinuation and death associated with surgically operable cancer in South-East Asia: results from the ACTION Study. Surgery. 2015;157(6):971–82. doi:10.1016/j.surg.2015.02.012.
7. Mahal A, Karan A, Fan VY, Engelgau M. The economic burden of cancers on Indian households. PloS One. 2013;8(8):e71853. doi:10.1371/journal.pone.0071853.
8. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol. 2009;62(10):e1–34. doi:10.1016/j.jclinepi.2009.06.006.
9. National Institutes of Health. Quality assessment tool for observational cohort and cross-sectional studies. 2014. Available from: http://www.nhlbi.nih.gov/health-pro/guidelines/in-develop/cardiovascular-risk-reduction/tools/cohort. Accessed 10 Aug 2016.
10. Bestvina CM, Zullig LL, Rushing C, et al. Patient-oncologist cost communication, financial distress, and medication adherence. J Oncol Pract. 2014;10(3):162–7. doi:10.1200/jop.2014.001406.
11. Davidoff AJ, Erten M, Shaffer T, et al. Out-of-pocket health care expenditure burden for Medicare beneficiaries with cancer. Cancer. 2013;119(6):1257–65. doi:10.1002/cncr.27848.
12. Fenn KM, Evans SB, McCorkle R, et al. Impact of financial burden of cancer on survivors’ quality of life. J Oncol Pract. 2014;10(5):332–8. doi:10.1200/jop.2013.001322.
13. Goodwin JA, Coleman EA, Sullivan E, et al. Personal financial effects of multiple myeloma and its treatment. Cancer Nurs. 2013;36(4):301–8. doi:10.1097/NCC.0b013e3182693522.
14. Jagsi R, Pottow JA, Griffith KA, et al. Long-term financial burden of breast cancer: experiences of a diverse cohort of survivors identified through population-based registries. J Clin Oncol. 2014;32(12):1269–76. doi:10.1200/jco.2013.53.0956.
15. Kaisaeng N, Harpe SE, Carroll NV. Out-of-pocket costs and oral cancer medication discontinuation in the elderly. J Manage Care Specialty Pharm. 2014;20(7):669–75. doi:10.18553/jmcp.2014.20.7.669.
16. Kale HP, Carroll NV. Self-reported financial burden of cancer care and its effect on physical and mental health-related quality of life among US cancer survivors. Cancer. 2016;122(8):283–9. doi:10.1002/cncr.29808.
17. Kent EE, Forsythe LP, Yabroff KR, et al. Are survivors who report cancer-related financial problems more likely to forgo or delay medical care? Cancer. 2013;119(20):3710–7. doi:10.1002/cncr.28262.
18. Khera N, Chang YH, Hashmi S, et al. Financial burden in recipients of allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transpl. 2014;20(9):1375–81. doi:10.1016/j.bbmt.2014.05.011.
19. Pisu M, Kenzik KM, Oster RA, et al. Economic hardship of minority and non-minority cancer survivors 1 year after diagnosis: another long-term effect of cancer? Cancer. 2015;121(8):1257–64. doi:10.1002/cncr.29206.
20. Ramsey S, Blough D, Kirchhoff A, et al. Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood). 2013;32(6):1143–52. doi:10.1377/hlthaff.2012.1263.
21. Stump TK, Eghan N, Egleston BL, et al. Cost concerns of patients with cancer. J Oncol Pract. 2013;9(5):251–7. doi:10.1200/jop.2013.000929.
22. Yabroff KR, Dowling EC, Guy GP Jr, et al. Financial hardship associated with cancer in the United States: findings from a population-based sample of adult cancer survivors. J Clin Oncol. 2016;34(3):259–67. doi:10.1200/jco.2015.62.0468.
23. Tucker-Seeley RD, Abel GA, Uno H, Prigerson H. Financial hardship and the intensity of medical care received near death. Psychooncology. 2015;24(5):572–8. doi:10.1002/pon.3624.
24. Chan A, Chiang YY, Low XH, et al. Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. Support Care Cancer. 2013;21(12):3509–17. doi:10.1007/s00520-013-1930-4.
25. You CH, Kang S, Kwon YD, Choi JH. Time trend of out-of-pocket expenditure among cancer inpatients: evidence from Korean tertiary hospitals. Asian Pac J Cancer Prev. 2013;14(11):6985–9.
26. Sharp L, Carsin AE, Timmons A. Associations between cancer-related financial stress and strain and psychological well-being among individuals living with cancer. Psychooncology. 2013;22(4):745–55. doi:10.1002/pon.3055.
27. Sharp L, Timmons A. Pre-diagnosis employment status and financial circumstances predict cancer-related financial stress and strain among breast and prostate cancer survivors. Support Care Cancer. 2016;24(2):699–709. doi:10.1007/s00520-015-2832-4.
28. Baili P, Di Salvo F, de Lorenzo F, et al. Out-of-pocket costs for cancer survivors between 5 and 10 years from diagnosis: an Italian population-based study. Support Care Cancer. 2016;24(5):2225–33. doi:10.1007/s00520-015-3019-8.
29. de Oliveira C, Bremner KE, Ni A, et al. Patient time and out-of-pocket costs for long-term prostate cancer survivors in Ontario, Canada. J Cancer Surviv. 2014;8(1):9–20. doi:10.1007/s11764-013-0305-7.
30. Lauzier S, Levesque P, Mondor M, et al. Out-of-pocket costs in the year after early breast cancer among Canadian women and spouses. J Natl Cancer Inst. 2013;105(4):280–92. doi:10.1093/jnci/djs512.
31. Gordon LG, Walker SM, Mervin MC, et al. Financial toxicity: a potential side effect of prostate cancer treatment among Australian men. Eur J Cancer Care (Engl). 2015. doi:10.1111/ecc.12392 [Epub ahead of print].
32. Kimman M, Jan S, Yip CH, et al. Catastrophic health expenditure and 12-month mortality associated with cancer in Southeast Asia: results from a longitudinal study in eight countries. BMC Med. 2015;13:190. doi:10.1186/s12916-015-0433-1.
33. Azzani M, Roslani AC, Su TT. The perceived cancer-related financial hardship among patients and their families: a systematic review. Support Care Cancer. 2015;23(3):889–98. doi:10.1007/s00520-014-2474-y.
34. de Souza JA, Yap BJ, Hlubocky FJ, et al. The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer. 2014;120(20):3245–53. doi:10.1002/cncr.28814.
35. Bouwmans C, Krol M, Severens H, et al. The iMTA Productivity Cost Questionnaire: a standardized instrument for measuring and valuing health-related productivity losses. Value Health. 2015;18(6):753–8. doi:10.1016/j.jval.2015.05.009.
36. Johar M, Mu C, Van Gool K, Wong CY. Bleeding hearts, profiteers, or both: specialist physician fees in an unregulated market. Health Econ. 2016. doi:10.1002/hec.3317 [Epub ahead of print].
37. O’Connor JM, Kircher SM, de Souza JA. Financial toxicity in cancer care. J Commun Support Oncol. 2016;14(3):101–6. doi:10.12788/jcso.0239.
38. Scott AM. Health technology assessment in Australia: a role for clinical registries? Aust Health Rev. 2016. doi:10.1071/AH15109 [Epub ahead of print].
39. Wortley S, Tong A, Howard K. Community views and perspectives on public engagement in health technology assessment decision making. Aust Health Rev. 2016. doi:10.1071/AH15221 [Epub ahead of print].
40. Greer JA, Amoyal N, Nisotel L, et al. A systematic review of adherence to oral antineoplastic therapies. Oncologist. 2016;21(3):354–76. doi:10.1634/theoncologist.2015-0405.
41. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487–97.
42. Tucker-Seeley RD, Abel GA, Uno H, Prigerson H. Financial hardship and the intensity of medical care received near death. Psychooncology. 2015;24(5):572–8. doi:10.1002/pon.3624.